Quietmind Foundation to Offer JuveLume Acne Products in the US for Non-Invasive Improvement of Facial Scarring and Unwanted Facial Pigmentation

PLYMOUTH MEETING, PA--(Marketwired - Jul 31, 2013) - Quietmind Foundation, the Plymouth Meeting, PA-based research non-profit that focuses on drug-free, non-invasive technologies to enhance health and improve treatments for a wide range of disorders, has exclusive US licensing for a new acne treatment product line developed by two medical professionals from the United Kingdom. Retired Eye Specialist Mr. Jim Haslam and GP Dr. Gordon Dougal have introduced JuveLume, a new, non-invasive treatment for facial scarring and unwanted facial pigmentation. A pilot study demonstrated 95% efficacy in the subjects treated achieving statistical significance compared to base line.

Haslam and Dougal originated the concept after observing the positive cosmetic effects of the technology in reducing the depth of lines, wrinkles, and size of the bags under the eyes, confirmed in double blind clinical trials. The proposed mechanism of action of the 1072nm low-level light technology was thought to involve an increase in the elastin collagen ratio in the skin. The medical duo then reasoned that if this were the case, when applied to facial scarring, even if decades old, an increase in elastin within the epidermis of the skin would result in a smoother contour to the skin.

Unwanted facial pigmentation is often associated with unwanted facial scarring, which stimulates melanin production especially in pigmented skin types. The pilot study was designed to evaluate any form of facial scarring such as surgical scars as well as scars occurring as a result of acne. A secondary end point assessment was that of assessing unwanted facial pigmentation often known as melasma.

Compared to baseline, JuveLume (www.juvelume.us) improved facial contours (http://www.juvelume.us/gallery/facial-scarring) and reduced unwanted facial pigmentation (http://www.juvelume.us/gallery/unwanted-facial-pigmentation), achieving a high degree of statistical significance (p=0.0004).

There are currently three products in the JuveLume facial skin treatment product line. The first is JuveLume M, which is the smallest version of the product. It will only be effective on small areas of facial scarring. The second is JuveLume, which is the average size device. The third is JuveLume A, which is designed to treat active acne as well as unwanted facial pigmentation and scarring.

According to one participant in the pilot study, "I have been using the acne device for a few months -- amazing product! My skin is quite sensitive and I could not use most acne products. This acne device helps my skin when nothing else would. I would never be without it."

To see prices and to purchase these products, please visit www.JuveLume.us.

Quietmind Foundation integrates innovative research, customized applications of biofeedback, and cutting-edge neuroscience technology into everyday and working life to help people and organizations achieve peak performance. For more information, contact: Quietmind Foundation, 521 Plymouth Rd. Suite 106 Plymouth Meeting, PA 19462, 610-940-0488, www.quietmindfdn.org.